Rapid relief for treatment-resistant depression.

Spravato® (esketamine) and ketamine are related medications that work through similar neurobiological pathways involved in mood regulation and neuroplasticity.

Spravato® is an FDA-approved nasal spray specifically indicated for treatment-resistant depression and certain patients with major depressive disorder and acute suicidal thoughts or behaviors. Ketamine has been used safely in medicine for decades and may be prescribed off-label for depression and other psychiatric conditions.

While the treatments are related, they differ in formulation, FDA approval status, administration methods, treatment protocols, and insurance coverage. Both may be effective options for patients who have not responded adequately to traditional antidepressant treatments.

Yes. Wave Treatment Centers offers both Spravato® and ketamine-based treatments as part of our interventional psychiatry program.

Because every patient has a unique clinical history and treatment response, we perform a comprehensive evaluation to determine which treatment option may be most appropriate based on symptoms, prior treatments, medical considerations, and treatment goals.

There is no single treatment that is best for everyone. Factors such as diagnosis, previous medication response, insurance coverage, treatment history, medical conditions, and personal preferences all play a role in treatment selection.

During your evaluation, we will review these factors and discuss whether Spravato®, ketamine-based treatment, TMS, medication optimization, or another approach may be the most appropriate next step.

Spravato® is typically considered for adults with treatment-resistant depression who have not responded adequately to antidepressant medications.

Eligibility is determined after a psychiatric evaluation.

Spravato® (esketamine) is an FDA-approved nasal spray medication used to treat treatment-resistant depression and certain patients with major depressive disorder and acute suicidal thoughts or behaviors. It is administered under medical supervision in a certified clinical setting.

Spravato® works differently from traditional antidepressants. It targets glutamate pathways in the brain, which may lead to faster symptom improvement in some patients.

Spravato® is administered in a certified medical setting under clinical supervision.

After self-administering the medication under staff guidance, patients remain in the clinic for approximately two hours of observation and monitoring. During this time, they are seated in a comfortable setting and may rest, listen to music, read, or simply relax while the effects of the medication gradually take effect and then wear off.

Common experiences during treatment may include relaxation, mild dissociation, or perceptual changes, which are temporary and monitored closely by clinical staff.

Because effects may persist after the monitoring period, patients may not drive themselves home following treatment and must arrange transportation.

Some patients notice improvement within hours to days, while others may require several weeks of treatment sessions before experiencing significant benefit.

Response varies by individual.

Spravato® is typically administered twice weekly during the initial phase, with frequency gradually reduced over time based on clinical response.

Treatment duration is individualized.

Spravato® is often covered by commercial insurance plans when medical criteria are met. Coverage varies, and our office assists with verification and authorization when appropriate.

Coverage for ketamine-based treatments varies depending on the treatment type and insurance plan. Unlike Spravato®, which is FDA-approved for treatment-resistant depression, ketamine is often used off-label in psychiatry and may not be covered by insurance.

During your consultation, we can discuss treatment options, expected costs, and whether insurance reimbursement may be available in your specific situation.